McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why McKesson (MCK) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is Why Growth Investors Should Buy McKesson (MCK) Now
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
MCK Q2 Earnings Beat, Sales Miss, '26 EPS View Up, Stock Down
McKesson posts a strong Q2 earnings beat but a slight sales miss, lifts its 2026 EPS outlook on solid specialty and tech segment growth.
McKesson Corporation (MCK) Q2 2026 Earnings Call Transcript
McKesson Corporation ( MCK ) Q2 2026 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jeni Dominguez - Head of Investor Relations Brian Tyler - CEO & Director Britt Vitalone - Executive VP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Brian Tanquilut - Jefferies LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Charles Rhyee - TD Cowen, Research Division Eric Percher - Nephron Research LLC Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division Allen Lutz - BofA Securities, Research Division Erin Wilson Wright - Morgan Stanley, Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division George Hill - Deutsche Bank AG, Research Division Michael Cherny - Leerink Partners LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Presentation Operator Welcome to McKesson's Second Quarter Fiscal 2026 Earnings Conference Call. Please be advised that today's conference is being recorded.
McKesson (MCK) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
McKesson (MCK) Surpasses Q2 Earnings Estimates
McKesson (MCK) came out with quarterly earnings of $9.86 per share, beating the Zacks Consensus Estimate of $8.92 per share. This compares to earnings of $7.07 per share a year ago.
Will Strong Segmental Performance Drive MCK's Top Line in Q2?
McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know
McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
